✦ LIBER ✦

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

✍ Scribed by Kenneth J. Pienta; Bruce G. Redman; Rajesh Bandekar; Myla Strawderman; Kemp Cease; Peggy S. Esper; Harmesh Naik; David C. Smith

Book ID: 119486889
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 750 KB
Volume: 50
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(97)00228-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly paclitaxel, estramustine phosphat

Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial

✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p

Oral estramustine and oral etoposide for

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

✍ Meletios A. Dimopoulos; Christos Panopoulos; Christina Bamia; Charalambos Delive 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 542 KB

Oral estramustine plus oral etoposide in

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

✍ Alfredo Berruti; Enrica Fara; Marcello Tucci; Roberto Tarabuzzi; Alessandra Mosc 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 163 KB

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over

Phase II Evaluation of Oral Estramustine

Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma

✍ Niklas J. Mackler; Kenneth J. Pienta; Rodney L. Dunn; Kathleen A. Cooney; Bruce 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 127 KB

Oral etoposide in the treatment of hormo

Oral etoposide in the treatment of hormone-refractory prostate cancer

✍ Maha H. Hussain; Kenneth J. Pienta; Bruce G. Redman; Glenn D. Cummings; Lawrence 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views